PAA

5.13%

20.5¢

PHARMAUST LIMITED

Market Cap $99.65M Add to my watchlist

Healthcare

PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for... PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The Company’s segments include Corporate and Research. The Company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The Company's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The Company is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. It is focused on starting Phase II/III clinical study of MPL. It has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. It is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.More

RCE'S BREAKTHROUGH

Synthetic anti-infective developer Recce Pharmaceuticals Ltd (ASX:RCE) has made inroads for recognition of its RECCE® 327 Gel (or R327G) as a topical treatment for burn wound infections, gaining a US$2 million grant from the US Department of Defense...

Latest Threads

Tag

Subject

PAA

Pharmaust - Media & News

18:23

27K

18:23

Last post Nickporthcawl

27K

PAA

Ann: PharmAust Completes Share Purchase Plan

26/07/24

21K

26/07/24

Last post Dryasachip

21K

PAA Biotech

PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial

14 15 16

26/07/24

940

247K

26/07/24

Last post NZ Trader

940

247K

PAA Algorithmic Trading

Stop the rort

25/07/24

1.0K

25/07/24

Last post Captain Goodvybes

1.0K

PAA

Ann: Application for quotation of securities - PAA

25/07/24

414

25/07/24

Last post

ASX News

414

PAA

PAA Chart

3 4 5

23/07/24

297

84K

23/07/24

Last post NZ Trader

297

84K

PAA

Ann: Monepantel Selected for Entry into HEALEY ALS Platform Trial

18/07/24

17K

18/07/24

Last post mc3456

17K

PAA

Ann: Investor Briefings & Webinar Notice

18/07/24

22K

18/07/24

Last post Nickporthcawl

22K

See All Discussions

Timeline

Application for quotation of securities - PAA
25 Jul 08:26	Share

PharmAust Completes Share Purchase Plan
24 Jul 09:02	Share

Investor Update - HEALEY ALS Platform Trial Selection
15 Jul 08:49	Share

Monepantel Selected for Entry into HEALEY ALS Platform Trial
15 Jul 08:42	Share

Investor Briefings & Webinar Notice
08 Jul 11:25	Share

PharmAust Granted SME Status by European Medicines Agency
01 Jul 08:52	Share

Section 708A Cleansing Statement
28 Jun 09:37	Share

Notification regarding unquoted securities - PAA
28 Jun 09:28	Share

Application for quotation of securities - PAA
28 Jun 09:15	Share

Application for quotation of securities - PAA
28 Jun 09:12	Share

Share Purchase Plan Offer Booklet
28 Jun 08:36	Share

Share Purchase Plan Cleansing Notice
28 Jun 08:18	Share

Application for quotation of securities - PAA
27 Jun 11:15	Share

PharmAust Presentation
21 Jun 13:15	Share

Proposed issue of securities - PAA
21 Jun 09:24	Share

PharmAust raises $10 million via Placement and announces SPP
21 Jun 09:24	Share

Initial Director's Interest Notice - K.MacFarlane
19 Jun 19:16	Share

Trading Halt
19 Jun 09:17	Share

PharmAust's Phase 1 Study Data Presented at Major Conference
18 Jun 09:38	Share

Appointment of Non-Executive Director
17 Jun 09:18	Share

OLE Study update reveals impressive Survival Data
05 Jun 09:23	Share

Initial Director's Interest Notice - M.Thurn
04 Jun 17:34	Share

Final Director's Interest Notice - J.Clark
04 Jun 17:31	Share

Executive team strengthened, appointment of MD/CEO & new CSO
31 May 08:26	Share

Change of Registered Office and Principal Place of Business
28 May 10:03	Share

Appointment of Company Secretary
24 May 08:18	Share

Investor Webinar Presentation
17 May 18:30	Share

PharmAust receives Orphan Drug Designation for monepantel
17 May 09:58	Share

Initial Director's Interest Notice
17 May 09:13	Share

Final Director's Interest Notice
17 May 09:09	Share

View More

(20min delay)
Last 20.5¢		Change 0.010(5.13%)		Mkt cap ! $99.65M

Open	High	Low	Value	Volume
19.5¢	20.5¢	19.5¢	$95.38K	475.2K

Buyers (Bids)

No.	Vol.	Price($)
3	135256	20.0¢

Sellers (Offers)

Price($)	Vol.	No.
20.5¢	79851	3

View Market Depth

No.	Vol.	Price($)
3	135256	0.200
9	87953	0.195
13	840004	0.190
12	226560	0.185
18	352803	0.180

Price($)	Vol.	No.
0.205	79851	3
0.210	269460	5
0.215	103895	2
0.220	506039	7
0.225	420666	1

Last trade - 16.10pm 26/07/2024 (20 minute delay)


Last 20.5¢		Change 0.010 ( 2.50 %)
Open	High	Low	Volume
20.0¢	20.5¢	20.0¢	212429
Last updated 15.22pm 26/07/2024 ?

PAA (ASX) Chart

PHARMAUST LIMITED

Latest Threads

Timeline

Featured News

Latest Videos

PharmAust (ASX:PAA) reports ongoing positive outcomes for canine cancer treatment

07 Mar 2023 14:53 (AEDT)

PharmAust (ASX:PAA) to gain European patent for cancer-killing MPL combinations

28 Feb 2023 10:59 (AEDT)

PharmAust (ASX:PAA) doses first patient of MND trial's second cohort

20 Feb 2023 14:00 (AEDT)

Latest Articles

PharmAust reappoints MD and resets its sights on MND battle

Biotechnical company PharmAust has reappointed Dr Michael Thurn as Managing Director and and Dr Nicky Wallis as Chief Scientific Officer.

PharmAust CEO's sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of its CEO, Dr. Michael Thurn.

PharmAust teams up with Berry Consultants for phase 2/3 MND study

PharmAust (ASX:PAA) is collaborating with renowned clinical study design expert, Berry Consultants, to design and analyse its planned phase 2/3 study for monepantel in patients with MND and ALS.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News